



**INOVA[®] FAIRFAX
HOSPITAL**

*Center for Liver Diseases
Inova Fairfax Hospital
3300 Gallows Road
Falls Church, Virginia 22042*

*Tel 703 776-3182
Fax 703 776-4386*

January 4, 2023

Michael Kram, M.D.

Re: Permission to use photomicrographs

Dear Dr Kram:

You are welcome to use the three requested photographs of liver biopsies with immunostains for galectin-3 in your paper submitted to World Journal of Hepatology. The photographs have no copyright, and there are no restrictions on their use.

Sincerely,

Zachary D. Goodman, M.D., Ph.D.
Director, Liver Pathology Research and Consultation
Center for Liver Diseases and Department of Pathology
Inova Fairfax Hospital

insert



Permission to use IHC slides and separate original images of the slides as well as a permission form for World Journal of Hepatology Galectin 3 inhibition publication > [View](#)



Michael Kram michaelkram@gmail.com

To Zachary Goodman, PhD

Mon, Dec 26, 2017

Dear Dr. Goodman,

Dr. Pat Boudes has kindly provided me with an introduction to you

I have authored a review of Galectin 3 inhibition that has been accepted by the World Journal of Hepatology

The Science Editor has asked for two remaining issues:

- 1) a permission release from you for me to use the figure(s)
- 2) for purposes of manuscript publication they would like separate image files of A, B, C. (So that there is no confusion I have enclosed the manuscript with the figure- labeled A, B, C and text.)


I have acknowledged your contribution and I thank you in advance. Please note that the initial manuscript had a very general figure of the Galectin 3 molecule and the reviewers wanted a figure that brought together the activated Galectin 3 macrophage. Your IHC staining of normal, NAAG1, and NAAG1 cells with a Galectin 3 antibody sealed the deal.

Thank you once again, and I hope this is not too much trouble for you.

Best,

Michael Kram

One attachment - Scanned by Gmail



Goodman, Zachary

Hi Michael, it was nice talking to you today. Attached is a letter of permission and original copies of the 3 figures. Best of luck, Zach From: Michael Kram

----- Forwarded message -----
 From: Pol Boudes <boudes@galectintherapeutics.com>
 Date: Mon, Dec 26, 2022 at 4:38 PM
 Subject: Introduction
 To: Zachary Goodman <Zachary.Goodman@inova.org>
 Cc: Michael Kram <michaelkrammd@gmail.com>

69

Dear Zack,

Dr. Kram is an hepatologist from New York City.
 Michael has written a review on galectin-3 and its inhibition for the treatment of NASH cirrhosis.
 The paper has been accepted for publication in the International Journal of Hepatology.

2

Michael was very interested to use the images of galectin-3 immunostaining that you presented on our AASLD poster.
 For this he would need your permission and, also, to obtain the original images as the editor has some formatting requests.

I am cc'ing Michael, it is probably best for him to contact you directly and share his hopes.

is
label

Thanks you so much for your help Zack.

+

Best,

fts

Pol

Pol F. Boudes, MD
 Chief Medical Officer
 Galectin Therapeutics
 4960 Peachtree Industrial Boulevard
 Suite 240
 Norcross, GA 30071
 boudes@galectinrx.com
 The NAVIGATE Study Clinical Trial in NASH Cirrhosis (navigatenash.com)
 cell: 925-818-3444

----- Forwarded message -----
 From: Pol Boudes <boudes@galectintherapeutics.com>
 Date: Mon, Dec 26, 2022 at 4:38 PM
 Subject: Introduction
 To: Zachary Goodman <Zachary.Goodman@inova.org>
 Cc: Michael Kram <michaelkrammd@gmail.com>

69

Dear Zack,

Dr. Kram is an hepatologist from New York City.
 Michael has written a review on galectin-3 and its inhibition for the treatment of NASH cirrhosis.
 The paper has been accepted for publication in the International Journal of Hepatology.

2

Michael was very interested to use the images of galectin-3 immunostaining that you presented on our AASLD poster.
 For this he would need your permission and, also, to obtain the original images as the editor has some formatting requests.

I am cc'ing Michael, it is probably best for him to contact you directly and share his hopes.

is

label

Thanks you so much for your help Zack.

+

fts

Best,

Pol

Pol F. Boudes, MD
 Chief Medical Officer
 Galectin Therapeutics
 4960 Peachtree Industrial Boulevard
 Suite 240
 Norcross, GA 30071
 boudes@galectinrx.com
 The NAVIGATE Study Clinical Trial in NASH Cirrhosis (navigatenash.com)
 cell: 925-818-3444

M

Michael Kram

Dear Dr. Goodman, Dr. Pol Boudes has kindly provided me with an introduction to you. I have authored a review of Galectin 3 inhibition

G

Goodman, Zachary

to me ▾

Hi Michael,

It was nice talking to you today. Attached is a letter of permission and original copies of the 3 figures.

Best of luck.

Zack

From: Michael Kram <michaelkrammd@gmail.com>
Sent: Monday, December 26, 2022 6:01 PM
To: Goodman, Zachary <Zachary.Goodman@inova.org>
Cc: Pol Boudes <Boudes@galactintherapeutics.com>
Subject: Permission to use IHC slides and separate original images of the slides as well as a permission form for World Journal of Hepatology

*** ATTENTION: This email originated from outside of Inova. Please proceed with caution if asked to click links or open attachments ***

4 Attachments - Scanned by Gmail

